News & Events

April 10, 2018

VIDAC PHARMA TO PRESENT A POSTER AT THE 2018 AACR ANNUAL MEETING 2018

Jerusalem, Israel, April 4, 2018 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will present a poster at the AACR Annual Meeting 2018 in Chicago, Illinois. The poster will be presented as…
January 23, 2018

VIDAC PHARMA TO PRESENT AT THE 2018 BIO CEO & INVESTOR CONFERENCE

Jerusalem, Israel, January 23, 2018 – Vidac Pharma, a clinical-stage oncology and dermatology-focused biopharmaceutical company, today announced that Oren M. Becker, PhD, President and Chief Executive Officer, will present at the 2018 BIO CEO & Investor…
December 06, 2017

VIDAC PHARMA TO PRESENT AT THE 2018 4TH ANNUAL DERMATOLOGY INNOVATION FORUM

Jerusalem, Israel, December 6, 2017 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will participate as Company Spotlight presenter at the 4th Annual Dermatology Innovation Forum. The…
October 12, 2017

VIDAC PHARMA REPORTS POSITIVE RESULTS FROM PHASE 2A PROOF-OF-CONCEPT TRIAL OF VDA-1102 OINTMENT IN ACTINIC KERATOSIS

Vidac Pharma reports positive results from Phase 2A Proof-of-concept trial of VDA-1102 OINTMENT in Actinic Keratosis Establishes that VDA-1102 ointment is well-tolerated, non-irritating and safe Demonstrates reduction of number of actinic keratosis lesions in…
Jan 01, 2017

VIDAC PHARMA APPOINTS CHIEF MEDICAL AND CHIEF SCIENCE OFFICERS

Jerusalem, Israel, January 1, 2017 – Vidac Pharma, a clinical-stage oncology-focused…
Dec 12, 2016

VIDAC PHARMA PHASE 2 STUDY OF VDA-1102 IN ACTINIC KERATOSIS MEETS INTERIM ANALYSIS CRITERION

Jerusalem, Israel, December 12, 2016 – Vidac Pharma, a clinical-stage oncology-focused…
Jul 29, 2016

VIDAC PHARMA ANNOUNCES THE INNITIATION OF A PHASE 2 STUDY OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS

Jerusalem, Israel, July 29, 2016 – Vidac Pharma, a clinical stage oncology focused…
Jun 30, 2016

VIDAC PHARMA COMPLETES PHASE 1A TRIAL OF VDA-1102 OINTMENT

Jerusalem, Israel, June 30, 2016 – Vidac Pharma, a clinical stage oncology focused…
Jun 29, 2016

Vidac Pharma Completes $9 Million Series A Financing I Advances Phase 2 Studies with VDA-1102 In Actinic Keratosis

Jerusalem, Israel, June 29, 2016 – Vidac Pharma, a privately-held clinical stage…
Feb 25, 2016

Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator

Jerusalem, Israel, February 25, 2016 – Vidac Pharma, a clinical stage drug development…

 

back Factsheet